Standout Papers

Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcome... 2019 2026 2021 2023 532
  1. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial (2019)
    Anders Widmark, Adalsteinn Gunnlaugsson et al. The Lancet

Immediate Impact

40 standout
Sub-graph 1 of 18

Citing Papers

Non-small-cell lung cancer
2024 Standout
Current advance of nanotechnology in diagnosis and treatment for malignant tumors
2024 Standout
2 intermediate papers

Works of M. Seke being referenced

Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial
2019 Standout
How to improve loco-regional control in stages IIIa–b NSCLC?
2008

Author Peers

Author Last Decade Papers Cites
M. Seke 595 20 67 428 173 6 703
Kirsten Björnlinger 551 17 52 417 166 6 650
Måns Agrup 560 17 98 411 181 14 722
Ruth Peter 438 15 103 338 184 11 620
C Marion 651 17 35 551 212 7 782
Magnus Lagerlund 592 17 128 446 178 10 810
Elizabeth O’Meara 605 12 39 451 225 10 733
Heather Chan 686 17 38 444 115 15 781
D. Lombardi 562 10 24 396 120 6 640
Alberto Bossi 592 17 92 238 192 12 669
Eric E. K. Yeoh 536 29 138 345 166 13 709

All Works

Loading papers...

Rankless by CCL
2026